SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required)
About
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required) is a federal funding opportunity from National Institutes of Health. This forecasted grant opportunity (FOR-OD-26-007) is available nationwide for eligible applicants.
The SBIR/STTR Commercialization Readiness Pilot (CRP) Program is a federal funding opportunity from the National Institutes of Health designed to support small businesses advancing innovative biomedical technologies toward market readiness. This program specifically targets companies that have completed or are conducting parent SB1 clinical trials, helping them bridge the critical gap between research success and commercial viability. The CRP Program is ideal for small business innovators and researchers who have demonstrated scientific merit through clinical validation and seek to accelerate their path to commercialization. Eligible applicants can access federal resources to strengthen business planning, regulatory strategy, manufacturing scale-up, and market entry strategies. This nationwide opportunity empowers entrepreneurs in the life sciences and biotechnology sectors to transform their clinical research into viable commercial products. By providing targeted support for commercialization readiness, the program helps bridge the funding valley of death that often prevents promising innovations from reaching patients and markets. Small businesses with clinical trial data and commercialization potential should explore this opportunity to strengthen their competitive position and access the resources necessary for successful product launch.
Grant Details
Funding Range
Varies by cycle
Grant Type
Federal
Application Cycle
As announced; varies by funding cycle
Best For
Small businesses with completed or ongoing parent SB1 clinical trials seeking commercialization support
Frequently Asked Questions
Who is eligible for SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required)?
This program is designed for small businesses that meet SBA size standards and have completed or are conducting parent SB1 clinical trials. Eligibility criteria for SBIR/STTR programs typically include small business status and U.S. ownership requirements. Since this program specifically requires a parent SB1 clinical trial, applicants must demonstrate prior NIH Small Business support and clinical trial activity. For detailed eligibility requirements and entity type qualifications, visit the official NIH SBIR/STTR website or the specific program announcement (FOR-OD-26-007).
How much funding does SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required) provide?
Funding amounts for the SBIR/STTR Commercialization Readiness Pilot Program vary by funding cycle and phase. Award amounts are typically determined based on the scope of work and commercialization readiness activities proposed. For current funding limits and specific award ranges for the active cycle, applicants should consult the official NIH SBIR/STTR program website or the relevant funding announcement (FOR-OD-26-007).
How do I apply for SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required)?
Applications for the SBIR/STTR Commercialization Readiness Pilot Program are typically submitted through Grants.gov and NIH eRA Commons. Applicants must prepare a comprehensive application including a research plan, commercialization strategy, budget justification, and evidence of prior SB1 clinical trial support. The application process requires small business certification and may include letters of support. Detailed instructions, deadlines, and submission requirements are available on the official NIH SBIR/STTR website. Review the specific program announcement for current guidelines and eligibility documentation.
What can SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required) funding be used for?
The Commercialization Readiness Pilot Program provides funding to advance small businesses beyond the clinical trial phase toward market readiness. Typical use of funds includes commercialization planning, regulatory pathway strategy, manufacturing scale-up, intellectual property protection, market analysis, business model development, and other activities that strengthen the path to product commercialization. The program emphasizes activities that transition promising clinical innovations into viable commercial products. For specific guidance on allowable uses of funds, consult the official program announcement and NIH guidelines.
Last updated: March 1, 2026